The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Monoclonal antibodies inhibit prion replication and delay the development of prion disease
Open accessAbstract
Prion diseases such as Creutzfeldt-Jakob disease (CJD) are fatal, neuro-degenerative disorders with no known therapy. A proportion of the UK population has been exposed to a bovine spongiform encephalopathy-like prion strain and are at risk of developing variant CJD. A hallmark of prion disease is the transformation of normal cellular prion protein (PrP(C)) into an infectious disease-associated isoform, PrP(Sc). Recent in vitro studies indicate that anti-PrP monoclonal antibodies with little or no affinity for PrP(Sc) can prevent the incorporation of PrP(C) into propagating prions. We therefore investigated in a murine scrapie model whether anti-PrP monoclonal antibodies show similar inhibitory effects on prion replication in vivo. We found that peripheral PrP(Sc) levels and prion infectivity were markedly reduced, even when the antibodies were first administered at the point of near maximal accumulation of PrP(Sc) in the spleen. Furthermore, animals in which the treatment was continued remained healthy for over 300 days after equivalent untreated animals had succumbed to the disease. These findings indicate that immunotherapeutic strategies for human prion diseases are worth pursuing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
A new variant of Creutzfeldt-Jakob disease in the UK
Will, R. G., Ironside, J. W., Zeidler, M., Estibeiro, K., Cousens, S. N., Smith, P. G., Alperovitch, A., Poser, S., Pocchiari, M., & Hofman, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91412-9 · Cited by 2,707
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent
Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttie, A., McCardle, L., Chree, A., Hope, J., Birkett, C., et al. (1997) · Nature · doi:10.1038/39057 · Cited by 1,967
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J., & Hill, A. F. (1996) · Nature · doi:10.1038/383685a0 · Cited by 1,735
Self-citationNormal development and behaviour of mice lacking the neuronal cell-surface PrP protein
Büeler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H.-P., DeArmond, S. J., Prusiner, S. B., Aguet, M., & Weissmann, C. (1992) · Nature · doi:10.1038/356577a0 · Cited by 1,655
The same prion strain causes vCJD and BSE
Hill, A. F., Desbruslais, M., Joiner, S., Sidle, K. C. L., Gowland, I., Collinge, J., Doey, L. J., & Lantos, P. (1997) · Nature · doi:10.1038/38925 · Cited by 1,456
Self-citationNormal host prion protein necessary for scrapie-induced neurotoxicity
Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C., & Aguzzi, A. (1996) · Nature · doi:10.1038/379339a0 · Cited by 810
Self-citationWadsworth, J., Joiner, S., Hill, A., Campbell, T., Desbruslais, M., Luthert, P., & Collinge, J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05403-4 · Cited by 693
Self-citationAntibodies inhibit prion propagation and clear cell cultures of prion infectivity
Peretz, D., Williamson, R. A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulms, G., Mehlhorn, I. R., Legname, G., Wormald, M. R., Rudd, P. M., et al. (2001) · Nature · doi:10.1038/35089090 · Cited by 525
Cited by
Therapeutic approaches to protein-misfolding diseases
Cohen, F. E., & Kelly, J. W. (2003) · Nature · doi:10.1038/nature02265 · Cited by 800
Protein aggregation diseases: pathogenicity and therapeutic perspectives
Aguzzi, A., & O'Connor, T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3050 · Cited by 762
Aguzzi, A., & Polymenidou, M. (2004) · Cell · doi:10.1016/s0092-8674(03)01031-6 · Cited by 544
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Prions: Protein Aggregation and Infectious Diseases
Aguzzi, A., & Calella, A. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00006.2009 · Cited by 504
Cross-Linking Cellular Prion Protein Triggers Neuronal Apoptosis in Vivo
Solforosi, L., Criado, J. R., McGavern, D. B., Wirz, S., Sánchez-Alavez, M., Sugama, S., DeGiorgio, L. A., Volpe, B. T., Wiseman, E., Abalos, G., et al. (2004) · Science · doi:10.1126/science.1094273 · Cited by 366
Sporadic human prion diseases: molecular insights and diagnosis
Puoti, G., Bizzi, A., Forloni, G., Safar, J. G., Tagliavini, F., & Gambetti, P. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70063-7 · Cited by 365
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Bae, E.-J., Lee, H.-J., Rockenstein, E., Ho, D.-H., Park, E.-B., Yang, N.-Y., Desplats, P., Masliah, E., & Lee, S.-J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1292-12.2012 · Cited by 339
Transmissible spongiform encephalopathies
Collins, S. J., Lawson, V. A., & Masters, C. L. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15171-9 · Cited by 339
Insights into prion strains and neurotoxicity
Aguzzi, A., Heikenwalder, M., & Polymenidou, M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2204 · Cited by 329
A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions
Klöhn, P.-C., Stoltze, L., Flechsig, E., Enari, M., & Weissmann, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834432100 · Cited by 324
From conversion to aggregation: Protofibril formation of the prion protein
DeMarco, M. L., & Daggett, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307178101 · Cited by 314
Freir, D. B., Nicoll, A. J., Klyubin, I., Panico, S., Mc Donald, J. M., Risse, E., Asante, E. A., Farrow, M. A., Sessions, R. B., Saibil, H. R., et al. (2011) · Nature Communications · doi:10.1038/ncomms1341 · Cited by 293
Self-citationSwaminathan, R., Ravi, V. K., Kumar, S., Kumar, M. V. S., & Chandra, N. (2011) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/b978-0-12-386483-3.00003-3 · Cited by 291
Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein
Parkin, E. T., Watt, N. T., Hussain, I., Eckman, E. A., Eckman, C. B., Manson, J. C., Baybutt, H. N., Turner, A. J., & Hooper, N. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609621104 · Cited by 270
Inhibition of Amyloid Formation
Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 269
A systematic review of prion therapeutics in experimental models
Trevitt, C. R. (2006) · Brain · doi:10.1093/brain/awl150 · Cited by 263
Active and passive immunotherapy for neurodegenerative disorders
Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132
Crystal structure of human prion protein bound to a therapeutic antibody
Antonyuk, S. V., Trevitt, C. R., Strange, R. W., Jackson, G. S., Sangar, D., Batchelor, M., Cooper, S., Fraser, C., Jones, S., Georgiou, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809170106 · Cited by 124
Self-citationImmunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116
Staffaroni, A. M., Kramer, A. O., Casey, M., Kang, H., Rojas, J. C., Orrú, C. D., Caughey, B., Allen, I. E., Kramer, J. H., Rosen, H. J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1071 · Cited by 100
Truncated Prion Protein and Doppel Are Myelinotoxic in the Absence of Oligodendrocytic PrPC
Radovanovic, I., Braun, N., Giger, O. T., Mertz, K., Miele, G., Prinz, M., Navarro, B., & Aguzzi, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0328-05.2005 · Cited by 82
“Alternatively, PrP C may instruct oligodendrocytes to release factors necessary for axonal survival (Wilkins et al., 2003).”
BackgroundKlyubin, I., Nicoll, A. J., Khalili-Shirazi, A., Farmer, M., Canning, S., Mably, A., Linehan, J., Brown, A., Wakeling, M., Brandner, S., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3526-13.2014 · Cited by 74
“PRN100 retains key binding properties of ICMS18 As part of a program to develop a monoclonal anti-PrP antibody for passive immunotherapy of prion infection and disease, we have developed a fully humanized version of ICSM18, a highaffinity mouse monoclonal antibody effective in treating murine prion infection (White et…”
BackgroundSelf-citationSpinner, D. S., Kascsak, R. B., LaFauci, G., Meeker, H. C., Ye, X., Flory, M. J., Kim, J. I., Schuller-Levis, G. B., Levis, W. R., Wisniewski, T., et al. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1106665 · Cited by 54
“Our studies demonstrate that the ODN 1826 enhances adaptive/humoral immune responses to PrP in mice and therefore, also may greatly improve the efficacy of vaccination [60, 61, 64–66] and passive immunization [44, 59, 62, 63] against TSE infection.”
Background
Metadata
- Authors
- White, A. R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, D., Collinge, J., & Hawke, S.
- Venue
- Nature
- Published
- 2003-03
- Volume
- 422
- Issue
- 6927
- Pages
- 80-83
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2063553621
- Cited by
- 492
- References
- 26
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.